Brexpiprazole (Rexulti): how it differs from aripiprazole

Brexpiprazole, sold as Rexulti by Otsuka and Lundbeck, was approved by the FDA in 2015 for schizophrenia and as an adjunctive treatment for major depressive disorder. In 2023, it became the first medication FDA-approved for agitation associated with Alzheimer's dementia. It is sometimes described as a "next-generation aripiprazole" — same dopamine partial-agonist family, but with receptor binding tuned slightly differently, and a different feel for many patients.

The partial agonist concept

Most older antipsychotics block dopamine D2 receptors — when dopamine signalling is too high, blocking it reduces psychosis. Aripiprazole and brexpiprazole take a different approach: they are partial agonists at D2 receptors. They activate the receptor but only weakly. In high-dopamine environments, they reduce signalling (acting like an antagonist). In low-dopamine environments, they raise it. This is sometimes called a "dopamine system stabiliser" effect.

Where brexpiprazole differs from aripiprazole

Both drugs are partial agonists at dopamine D2 and serotonin 5-HT1A receptors and antagonists at 5-HT2A. Brexpiprazole has lower intrinsic activity at D2 receptors than aripiprazole — meaning it activates them less strongly even when binding. It also has higher affinity for several serotonin and adrenergic receptors. Clinically, this often translates to:

• Less activation and akathisia in many patients
• Slightly more sedation
• Generally smoother subjective feel

Direct head-to-head trials comparing the two are limited, so much of the comparison comes from cross-trial data and clinical experience. See our side-by-side comparison.

FDA-approved indications

• Schizophrenia in adults — acute and maintenance
• Adjunctive treatment of major depressive disorder in adults
• Agitation associated with Alzheimer's-type dementia (added in 2023)

Dosing

Per the FDA Rexulti label, schizophrenia dosing typically starts at 1 mg once daily for several days, increased gradually to a target of 2 to 4 mg once daily. For MDD adjunct, doses are lower (0.5 to 2 mg). For Alzheimer's-related agitation, dosing is started low and titrated slowly with attention to the boxed warning about increased mortality in dementia patients.

The Alzheimer's-agitation indication: a careful approval

Brexpiprazole's 2023 approval for agitation in Alzheimer's was the first time the FDA approved an antipsychotic for this use. The decision was controversial — antipsychotics carry an established increased mortality risk in dementia, reflected in the boxed warning that remains on the label. Approval was based on two trials showing modest but statistically significant reductions in agitation. The FDA emphasised that brexpiprazole should be used only when symptoms are severe, dangerous, or distressing and after non-drug interventions have been tried. The boxed warning remains.

Side effect profile

Akathisia

Less common than with aripiprazole in many comparisons, but still occurs — typically dose-related. See our akathisia article.

Weight gain and metabolic effects

Modest. Average weight gain in long-term studies is greater than with aripiprazole but less than with olanzapine or quetiapine. Metabolic monitoring is recommended.

Sedation

Mild to moderate, often manageable by dosing in the evening.

Movement side effects

Lower rates of EPS than high-potency typicals. Tardive dyskinesia risk is reduced compared with first-generation drugs but not zero.

Compulsive behaviours

Like aripiprazole, brexpiprazole has reports of pathological gambling, hypersexuality, and compulsive shopping or eating. The mechanism is thought to involve D3 receptor partial agonism. These effects are dose-related and reversible on stopping. Anyone starting or increasing brexpiprazole should be alerted to watch for new compulsive behaviours.

Drug interactions and metabolism

Brexpiprazole is metabolised by CYP2D6 and CYP3A4. Strong inhibitors of either enzyme can raise levels meaningfully; the FDA label provides specific dose-adjustment recommendations. CYP2D6 poor metabolisers (a genetic variant) need lower doses. Pharmacogenomic testing may help in some cases.

Who tends to do well on brexpiprazole

• People who responded reasonably to aripiprazole but found it too activating
• People with depression layered onto schizophrenia or psychotic features
• People who want a partial-agonist option with a smoother feel
• People who have had bad EPS on high-potency typicals

Who might choose differently

• People with very severe positive symptoms who may need a stronger D2 blocker
• People with prior compulsive behaviour issues
• People for whom cost is prohibitive — Rexulti remains brand-only in the US for now

Cost and access

Rexulti is brand-only in the US and expensive without insurance coverage. Manufacturer patient assistance programs and copay support may be available; see patient assistance programs.

Practical questions to ask your prescriber

• What did or did not work about aripiprazole if I have tried it before?
• Is brexpiprazole covered by my insurance?
• What dose target are we aiming for, and how long will we wait to judge response?
• What should I do if I notice new compulsive behaviours?

The big picture

Brexpiprazole sits in a useful middle space — same family as aripiprazole, often a smoother experience, with broader indications. It is not a dramatically more effective drug, but it can be a meaningfully different one for the right person. As with all antipsychotic decisions, the right answer depends on your symptom profile, prior response history, side effect tolerance, and insurance situation, all worked through carefully with a prescriber who knows you.

This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication.